Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial

Caroline Robert, Antoni Ribas, Jedd D. Wolchok, F. Stephen Hodi, Omid Hamid, Richard Kefford, Jeffrey S. Weber, Anthony M. Joshua, Wen Jen Hwu, Tara C. Gangadhar, Amita Patnaik, Roxana Dronca, Hassane Zarour, Richard W. Joseph, Peter Boasberg, Bartosz Chmielowski, Christine Mateus, Michael A. Postow, Kevin Gergich, Jeroen Elassaiss-SchaapXiaoyun Nicole Li, Robert Iannone, Scot W. Ebbinghaus, S. Peter Kang, Adil Daud

Research output: Contribution to journalArticlepeer-review

1257 Scopus citations

Fingerprint

Dive into the research topics of 'Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: A randomised dose-comparison cohort of a phase 1 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences